文献速递临床试验与 GCP基础与转化研究

SARS-CoV-2变异株mRNA疫苗加强针在健康成人中的安全性与免疫原性:中期分析

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
PubMed 文献 · Nat Med · 2021-09-15

该开放标签2a期试验纳入约6个月前完成两剂mRNA-1273基础免疫的受试者,评估单剂mRNA-1273或变异修饰加强针的安全性与免疫原性。中期分析显示加强前针对野生型D614G的中和抗体较基础免疫后1个月峰值下降,对Beta、Gamma、Delta变异株滴度低或检测不到;所有加强针安全耐受,mRNA-1273和mRNA-1273.211显著提高野生型滴度,所有加强针均提高关键变异株滴度至与基础免疫后野生型峰值相当。

要点

  • 基础免疫后约6个月中和抗体下降,对Beta、Gamma、Delta变异株滴度低或检测不到。
  • mRNA-1273及变异修饰加强针均安全耐受,可提高野生型和关键变异株中和滴度。
  • mRNA-1273和mRNA-1273.211对野生型D614G滴度提升有统计学显著性。

核心结论

  • mRNA-1273及变异修饰加强针安全耐受,可提高对野生型和关键变异株的中和抗体滴度。

研究设计与样本

  • 开放标签2a期试验,受试者为约6个月前完成两剂mRNA-1273基础免疫的临床试验参与者。
  • 中期探索性分析纳入四个加强组,每组n=20,仅报告初步描述性结果。

主要发现

  • 加强前针对野生型D614G的中和抗体较基础免疫后1个月峰值下降(P<0.0001)。
  • 加强前对B.1.351、P.1和B.1.617.2变异株的中和滴度低或检测不到。
  • 所有加强针使野生型D614G中和滴度数值上高于基础免疫后峰值,mRNA-1273和mRNA-1273.211显著(P<0.0001)。
  • 所有加强针提高关键变异株中和滴度,与基础免疫后野生型峰值统计学等效,对某些VOI滴度更优。

临床怎么用

  • 支持在基础免疫后约6个月使用mRNA加强针以提升对变异株的中和抗体水平。

局限性

  • 为正在进行的试验的探索性中期分析,仅初步描述性结果,每组n=20。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs) with decreased susceptibility to neutralization has generated interest in assessments of booster doses and variant-specific vaccines. Clinical trial participants who received a two-dose primary series of the COVID-19 vaccine mRNA-1273 approximately 6 months earlier entered an open-label phase 2a study ( NCT04405076 ) to evaluate the primary objectives of safety and immunogenicity of a single booster dose of mRNA-1273 or variant-modified mRNAs, including multivalent mRNA-1273.211. As the trial is currently ongoing, this exploratory interim analysis includes preliminary descriptive results only of four booster groups (n = 20 per group). Immediately before the booster dose, neutralizing antibodies against wild-type D614G virus had waned (P < 0.0001) relative to peak titers against wild-type D614G measured 1 month after the primary series, and neutralization titers against B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) VOCs were either low or undetectable. Both the mRNA-1273 booster and variant-modified boosters were safe and well-tolerated. All boosters, including mRNA-1273, numerically increased neutralization titers against the wild-type D614G virus compared to peak titers against wild-type D614G measured 1 month after the primary series; significant increases were observed for mRNA-1273 and mRNA-1273.211 (P < 0.0001). In addition, all boosters increased neutralization titers against key VOCs and VOIs, including B.1.351, P.1. and B.1.617.2, that were statistically equivalent to peak titers measured after the primary vaccine series against wild-type D614G virus, with superior titers against some VOIs. This trial is ongoing.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021. PMID: 34526698. doi:10.1038/s41591-021-01527-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。